The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). Naxitamab is FDA approved for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy, it may not be approved in the type of disease used in this study.
The goals of this part of the study are:
* Test the safety and tolerability of tipifarnib in combination with naxitimab in patients with cancer
* To determine the activity of study treatments chosen based on:
* How each subject responds to the study treatment
* How long a subject lives without their disease returning/progressing

Start Date01 Nov 2024

Sponsor / Collaborator

Hershey Medical Center

NCT05693090 / WithdrawnPhase 1

Phase 1 Study of Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.

Start Date01 Feb 2023

Sponsor / Collaborator

Kura Oncology, Inc.

NCT04997902 / RecruitingPhase 1/2

A Phase 1/2 Open-label, Biomarker-defined Cohort Trial to Evaluate the Safety, Determine the Recommended Combination Dosing, and Assess Early Antitumor Activity of Tipifarnib and Alpelisib for the Treatment of Adult Participants Who Have HRAS-overexpressing and/or PIK3CA-mutated and/or - Amplified Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

This phase 1/2 combination trial of tipifarnib, a farnesyltransferase inhibitor, and alpelisib, a PI3K inhibitor in participants with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) whose tumors overexpress the HRAS protein and/or are PIK3CA-mutated and/or PIK3CA-amplified.

Start Date07 Dec 2021

Sponsor / Collaborator

Kura Oncology, Inc.

100 Clinical Results associated with Tipifarnib

100 Translational Medicine associated with Tipifarnib

100 Patents (Medical) associated with Tipifarnib

383

Literatures (Medical) associated with Tipifarnib

10 Sep 2024·Blood Advances

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

Article

Author: Marín-Niebla, Ana ; Foss, Francine ; Rodriguez Izquierdo, Antonia ; Saunders, Andrew ; Witzig, Thomas ; Bendris, Nawal ; Leoni, Mollie ; de la Cruz Vicente, Fátima ; Advani, Ranjana ; Sokol, Lubomir ; Domingo-Domenech, Eva ; de Oña Navarrete, Raquel ; Kim, Won Seog ; Mackey, Julie ; Martín García-Sancho, Alejandro ; Roncero Vidal, Jose Maria ; Terol, María José

Abstract:

A phase 2, international, open-label, nonrandomized, single-arm trial was conducted to evaluate the efficacy and safety of tipifarnib, a farnesyltransferase inhibitor, as monotherapy for relapsed/refractory peripheral T-cell lymphoma (PTCL) and to evaluate tumor mutation profile as a biomarker of response. Adults with relapsed/refractory PTCL received tipifarnib 300 mg orally twice daily for 21 days in a 28-day cycle. The primary end point was objective response rate (ORR); secondary end points included ORR, progression-free survival (PFS), duration of response (DOR), and adverse events (AEs) in specific subtypes. Sixty-five patients with PTCL were enrolled: n = 38 angioimmunoblastic T-cell lymphoma (AITL), n = 25 PTCL not otherwise specified, and n = 2 other T-cell lymphomas. The ORR was 39.7% (95% confidence interval [CI], 28.1-52.5) in all patients and 56.3% (95% CI, 39.3-71.8) for AITL. Median PFS was 3.5 months overall (954% CI, 2.1-4.4), and 3.6 months (95% CI, 1.9-8.3) for AITL. Median DOR was 3.7 months (95% CI, 2.0-15.3), and greatest in patients with AITL (7.8 months; 95% CI, 2.0-16.3). The median overall survival was 32.8 months (95% CI, 14.4 to not applicable). Tipifarnib-related hematologic AEs were manageable and included neutropenia (43.1%), thrombocytopenia (36.9%), and anemia (30.8%); other tipifarnib-related AEs included nausea (29.2%) and diarrhea (27.7%). One treatment-related death occurred. Mutations in RhoA, DNMT3A, and IDH2 were seen in 60%, 33%, and 27%, respectively, in the AITL tipifarnib responder group vs 36%, 9%, and 9% in the nonresponder group. Tipifarnib monotherapy demonstrated encouraging clinical activity in heavily pretreated relapsed/refractory PTCL, especially in AITL, with a manageable safety profile. This trial was registered at www.ClinicalTrials.gov as #NCT02464228.

06 Sep 2024·ONCOGENE

Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors

Article

Author: Nigam, Aradhya ; Berman, Katherine ; Untch, Brian R ; Ho, Alan L ; Saqcena, Mahesh ; Venkatramani, Mandakini ; Chatila, Walid K ; Schultz, Nikolaus ; Walch, Henry ; Krishnamoorthy, Gnana P ; Fagin, James A

In the clinical development of farnesyltransferase inhibitors (FTIs) for HRAS-mutant tumors, responses varied by cancer type. Co-occurring mutations may affect responses. We aimed to uncover cooperative genetic events specific to HRAS-mutant tumors and to study their effect on sensitivity to FTIs. Using targeted sequencing data from the MSK-IMPACT and Dana-Farber Cancer Institute Genomic Evidence Neoplasia Information Exchange databases, we identified comutations that were observed predominantly in HRAS-mutant versus KRAS-mutant or NRAS-mutant cancers. HRAS-mutant cancers had a higher frequency of coaltered mutations (48.8%) in the MAPK, PI3K, or RTK pathway genes, compared with KRAS-mutant (41.4%) and NRAS-mutant (38.4%) cancers (p < 0.05). Class 3 BRAF, NF1, PTEN, and PIK3CA mutations were more prevalent in HRAS-mutant lineages. To study the effects of comutations on sensitivity to FTIs, Hras^G13R was transfected into "RASless" (Kras^lox/lox/Hras^-/-/Nras^-/-/RERT^ert/ert) mouse embryonic fibroblasts (MEFs), which sensitized nontransfected MEFs to tipifarnib. Comutation in the form of Pten or Nf1 deletion and Pik3ca^H1047R transduction led to resistance to tipifarnib in Hras^G13R-transfected MEFs in the presence or absence of Kras^WT, whereas Braf^G466E transduction led to resistance to tipifarnib only in the presence of Kras^WT. Combined treatment with tipifarnib and MEK inhibition sensitized cells to tipifarnib in all settings, including in MEFs with PI3K pathway comutations. HRAS-mutant tumors demonstrate lineage-dependent MAPK or PI3K pathway alterations, which confer resistance to tipifarnib. The combined use of FTIs and MEK inhibition is a promising strategy for HRAS-mutant tumors.

01 Sep 2024·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

An insight into sustainable and green chemistry approaches for the synthesis of quinoline derivatives as anticancer agents

Review

Author: Kumaraswamy, B ; Hosamani, Ketan R ; Hemalatha, K ; Aishwarya, Nimmagadda Venkata Satya Sai ; Pal, Rohit ; Matada, Gurubasavaraja Swamy Purawarga ; Aayishamma, I

Quinolones, a key class of heterocyclics, are gaining popularity among organic and medicinal chemists due to their promising properties. Quinoline, with its broad spectrum of action, plays a primordial role in chemotherapy for cancer. Drugs include lenvatinib and its structural derivatives carbozantinib and bosutinib, and tipifarnib are the popular anticancer agents. Owing to the importance of quinoline, there are several classical methods for the synthesis such as, such as Gould-Jacobs, Conrad-Limpach, Camps cyclization, Skraup, Doebnervon Miller, Combes, Friedlander, Pfitzinger, and Niementowski synthesis. These methods are well-commended for developing an infinite variety of quinoline analogues. However, these procedures are associated with several drawbacks such as long reaction times, use of hazardous chemicals or stoichiometric proportions, difficulty of working up conditions, high temperatures, organic solvents, and the presence of numerous steps, all of which have an impact on the environment and the economy. As a result, researchers are working hard to develop green quinoline compounds in the hopes of making groundbreaking discoveries in the realm of cancer. In this review, we have highlighted significant research on quinoline-based compounds and their structure-activity relationship (SAR). Furthermore, because of the significant economic and environmental health and safety (EHS) concerns, more research is being dedicated to the green synthesis of quinolone derivatives. The current review offers recent advances in quinoline derivatives as anticancer agents for green synthesis using microwave, ultrasound, and one-pot synthesis. We believe that our findings will provide useful insight and inspire more green research on this framework to produce powerful and selective quinoline derivatives.

News (Medical) associated with Tipifarnib

17 Sep 2024

·www.globenewswire.com

Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. “On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “His extensive experience in R&D and regulatory affairs, combined with his leadership across both large and emerging companies, will be invaluable as we advance our menin inhibitor and farnesyl transferase inhibitor (FTI) programs for cancer patients in need.” Dr. Vasconcelles currently serves as a Senior Advisor to the Life Sciences team at Frazier Healthcare Partners. Previously, he was Executive Vice President & Head of Research, Development, and Medical Affairs at ImmunoGen. Prior to ImmunoGen, he was the Chief Medical Officer and Head of the Medical and Scientific Organization at Flatiron Health, a wholly owned subsidiary of the Roche Group. Before that, he served as Chief Medical Officer at Unum Therapeutics. Prior to joining Unum, Dr. Vasconcelles spent several years at Takeda/Millennium as Senior Vice President and Head of the Oncology Therapy Area unit. Prior to Takeda/Millennium, he was Group Vice President and the Global Therapeutic Area Head of Transplant and Oncology at Genzyme Corporation. After Sanofi’s acquisition of Genzyme, Dr. Vasconcelles joined Sanofi Oncology as Head of Personalized Medicine and Companion Diagnostics. “I am eager to join Kura’s Board of Directors during a key inflection point in the company’s trajectory,” said Dr. Vasconcelles. “Kura’s innovative approach to precision oncology, particularly with their menin inhibitor program for acute leukemias, presents a remarkable opportunity to make a meaningful impact for patients. I look forward to working with the team to advance these promising therapies through the clinic and toward commercialization.” Dr. Vasconcelles also serves as a Board member of the Personalized Medicine Coalition and the Eastern New England American Cancer Society, a non-executive director of Molecular Partners, and a member of numerous Scientific Advisory Boards within the biopharmaceutical industry. From 1996 to 2021, Dr. Vasconcelles taught as a clinical instructor at the Harvard Medical School and was an associate physician at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. Dr. Vasconcelles received his B.A. and M.D. from Northwestern University. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Kura is evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of ziftomenib, potential benefits of combining ziftomenib with appropriate standards of care, and progress and expected timing of the ziftomenib program and clinical trials. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, applications and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s periodic and other filings with the Securities and Exchange Commission (SEC), including the Company’s Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 8, 2024, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investors:Pete De SpainExecutive Vice President, Investor Relations &Corporate Communications(858) 500-8833pete@kuraoncology.com Media:Cassidy McClainVice PresidentInizio Evoke Comms(619) 849-6009cassidy.mcclain@inizioevoke.com

Phase 1Phase 2Executive ChangeBreakthrough Therapy

10 Sep 2024

·www.globenewswire.com

Kura Oncology to Participate in Cantor Global Healthcare Conference

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming Cantor Global Healthcare Conference being held in New York. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 1:20 p.m. ET / 10:20 a.m. PT on September 17, 2024. A live audio webcast of the fireside chat will be available in the investor section of Kura’s website at www.kuraoncology.com with an archived replay available following the live event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Kura is evaluating KO-2806, a next-generation farnesyl transferase inhibitor (FTI), in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn. Contacts Investors:Pete De SpainExecutive Vice President, Investor Relations &Corporate Communications(858) 500-8833pete@kuraoncology.com Media:Cassidy McClainVice PresidentInizio Evoke Comms(619) 849-6009cassidy.mcclain@inizioevoke.com

Phase 2Phase 1Breakthrough Therapy

10 Aug 2024

·www.globenewswire.com

Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)

– Preclinical data suggest combination of ziftomenib and imatinib has potential to resensitize patients to imatinib and induce durable responses – – Proof-of-concept study evaluating ziftomenib and imatinib in patients with advanced GIST to begin in 1H 2025 – Aug. 08, 2024 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ziftomenib, the Company’s potent and selective menin inhibitor, for the treatment of advanced gastrointestinal stromal tumors (GIST). The Company plans to initiate a Phase 1 first-in-human study of ziftomenib in combination with imatinib, a targeted therapy approved for the treatment of GIST, in early 2025. “This important milestone represents the first IND clearance of a menin inhibitor to treat GIST, a solid tumor indication with limited treatment options for patients with advanced disease,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “Although imatinib is utilized in frontline GIST patients, many eventually develop resistance. Our preclinical data suggest ziftomenib has potential to resensitize patients to imatinib and induce deep, durable responses. We look forward to presenting the preclinical data for the combination at an upcoming scientific meeting and initiating a proof-of-concept clinical study early next year.” GIST is the most common form of sarcoma, characterized as KIT-dependent solid tumors. KIT inhibitors are associated with favorable outcomes for patients with GIST, and imatinib is the standard of care in this patient population. For patients who progress on imatinib, subsequent treatment options include other KIT inhibitors; however, these options are limited by moderate efficacy and challenging tolerability. The menin-MLL complex regulates KIT expression in GIST cells, and menin inhibitors display additive therapeutic activity with imatinib in imatinib-sensitive GIST models1. Preclinical data in imatinib-resistant PDX models suggest that ziftomenib in combination with imatinib has the potential to resensitize patients to imatinib and induce durable responses. Kura plans to initiate a proof-of-concept study evaluating ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure. Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn. 1 Hemming ML et al., Cancer Discov. 2022;12:1804-1823. The content above comes from the network. if any infringement, please contact us to modify.

INDBreakthrough Therapy

100 Deals associated with Tipifarnib

External Link

KEGG	Wiki	ATC	Drug Bank
D03720	Tipifarnib	-	DB04960

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	NDA/BLA	US	Johnson & Johnson	-
Acute Erythroblastic Leukemia	Phase 3	US	National Cancer Institute	18 Aug 2004
Acute Erythroblastic Leukemia	Phase 3	IL	National Cancer Institute	18 Aug 2004
Acute Erythroblastic Leukemia	Phase 3	PE	National Cancer Institute	18 Aug 2004
Acute Megakaryoblastic Leukemia	Phase 3	US	National Cancer Institute	18 Aug 2004
Acute Megakaryoblastic Leukemia	Phase 3	IL	National Cancer Institute	18 Aug 2004
Acute Megakaryoblastic Leukemia	Phase 3	PE	National Cancer Institute	18 Aug 2004
Acute Myeloid Leukemia with Myelodysplasia-Related Changes	Phase 3	US	National Cancer Institute	18 Aug 2004
Acute Myeloid Leukemia with Myelodysplasia-Related Changes	Phase 3	IL	National Cancer Institute	18 Aug 2004
Acute Myeloid Leukemia with Myelodysplasia-Related Changes	Phase 3	PE	National Cancer Institute	18 Aug 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02807272 (CMML/AML, CTgov)	Phase 2	Acute Myeloid Leukemia \| Chronic Myelomonocytic Leukemia \| Myelodysplastic Syndromes	44	tipifarnib (KRAS/NRAS WT)	gmyeihqqag(ppehtnzaos) = uzhpaisehi dpiiqqpmgw (tvljgfvoyk, ygxbgwvspo - tqduhxzaem) View more	-	17 Jul 2024
				tipifarnib (KRAS/NRAS Mut)	gmyeihqqag(ppehtnzaos) = imcpnvxnfh dpiiqqpmgw (tvljgfvoyk, mofwsaycsz - pihkwggzpj) View more
NCT02464228 (Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma, Pubmed)	Phase 2	Peripheral T-Cell Lymphoma RhoA \| DNMT3A \| IDH2	-	Tipifarnib 300 mg	ohgfksfari(duohglwovx) = fjsovyukxp ptygryyzyl (ssqpmpkril, 28.1 - 52.5) View more	Positive	11 Jul 2024
NCT02383927 (CTgov)	Phase 2	HRAS positive Solid Tumors \| Advanced Malignant Solid Neoplasm \| Squamous Cell Carcinoma of Head and Neck ... View more	63	Tipifarnib	txiqmprwny(bnqnvmsdhi) = fwvahnqsvc vuycjetcbs (ldntqdounv, hmsyuetvrk - civbeydvrj) View more	-	11 Jul 2024
NCT02464228 (PTCL \| Phase 2 study \| Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib for Relapsed/Refractory Peripheral T Cell Lymphoma, CTgov)	Phase 2	Peripheral T-Cell Lymphoma	65	tipifarnib (Cohort AITL)	mlpcsvbvzk(ovruktutnq) = wrbxkhfpia hmjjvcguaq (sknejfesot, qhoepfslza - ebnhalgqiz) View more	-	26 Jun 2024
				tipifarnib (Cohort PTCL-NOS)	mlpcsvbvzk(ovruktutnq) = tzxotsccpz hmjjvcguaq (sknejfesot, swwlhtjndp - cldevncanp) View more
NCT03496766 (CTgov)	Phase 2	Advanced Lung Squamous Cell Carcinoma \| Advanced Lung Non-Small Cell Squamous Carcinoma	9	Tipifarnib	ynizircmpn(kigmmrvvmq) = qbgpbwgpwy aebhhqzctj (jejretltlm, yahdigfema - rgdrklsqci) View more	-	29 Mar 2024
NCT03719690 (AIM-HN, ESMO2023) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck Second line HRAS Mutation	59	Tipifarnib (Pts with high VAF in mITT)	euwvdjikkv(wakgmysbzk) = mzkinrwtpd vxncmdbvkt (ioyivcjtyo, 0.10 - 0.34) View more	Positive	21 Oct 2023
				Tipifarnib (2 Line)	euwvdjikkv(wakgmysbzk) = qrbdcihydx vxncmdbvkt (ioyivcjtyo, 0.13 - 0.51)
AACR2022	Not Applicable	Squamous Cell Carcinoma of Head and Neck	-	Tipifarnib (HRAS mutant tumors)	hkusxcmwfa(sndkutoeov) = czlsdtdgsa ypcxqetfox (wwdhrxhwzb ) View more	-	15 Jun 2022
				Tipifarnib (HRAS wild-type tumors)	hkusxcmwfa(sndkutoeov) = kfakdahoku ypcxqetfox (wwdhrxhwzb ) View more
NCT02464228 (ASH2021) Manual	Phase 2	Peripheral T-Cell Lymphoma	65	Tipifarnib 300 mg	yilpqvxwhe(pszpztrjvz) = oefpautwxa drydvsmhdk (ytxwragohp ) View more	Positive	05 Nov 2021
				Tipifarnib 300 mg (pts with AITL)	yilpqvxwhe(pszpztrjvz) = iiqapxozdh drydvsmhdk (ytxwragohp ) View more
NCT02807272 (ESMO2021) Manual	Phase 2	Myelodysplastic-Myeloproliferative Diseases \| Chronic Myelomonocytic Leukemia KRAS Wild-type \| NRAS Wild-type \| KRAS Mutation ... View more	44	Tipifarnib	pdbioxpfve(wwduqgmdxl) = lluulorrbz lsyjzpybbo (mzdfwqfuqa ) View more	Positive	16 Sep 2021
NCT02383927 (Pubmed \| J Urol) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck HRAS Mutation	30	Tipifarnib	ndzeydxljx(fxtrmzidwt) = kvsbqzlguj wujupryscz (hzpiixwazt, 31.5 - 76.9) View more	Positive	10 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis